Previous studies supporting the potential efficacy of GLP-1 agonists have relied on secondary analyses of data collected in open trials [125-127] or a randomized controlled treatment trial for obesity without placebo control [128]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.